Stem cell-derived islet cell therapy shows promise for individuals with type 1 diabetes
June 26, 2023 -- An ongoing clinical trial for patients with type 1 diabetes (T1D) demonstrated the potential of stem cell-derived islet cell therapy, called VX-880, as a future treatment option for patients with type 1 diabetes (T1D), the American Diabetes Association (ADA) said on Friday. Read More
Rare disease discovered after scientists probe cause of inflammatory symptoms
June 22, 2023 -- Researchers have discovered a rare disease by running genetic, immunologic, and molecular assays in four patients. Read More
Bio-Techne to acquire Swiss spatial biology firm Lunaphore
June 22, 2023 -- Bio-Techne announced Thursday that it has reached an agreement to acquire Tolochenaz, Switzerland-based Lunaphore, a developer of fully automated spatial biology products. Read More
Genomics AI firm Genomenon acquires Boston Genetics
June 27, 2023 -- Genomenon on Tuesday said that it has acquired the genomics interpretation and curation firm Boston Genetics. Read More
Asep gets Canadian grant for development of peptide-based drug delivery vehicle
June 26, 2023 -- Asep Medical announced Friday that it has been awarded a grant by the NanoMedicines Innovation Network (NMIN) to develop a nanoparticle-formulated peptide solution as a drug delivery vehicle for treating chronic sinus infections caused by biofilms. Read More
Scanning ion conductance spectroscopy in study enables precise DNA identification
June 21, 2023 -- Researchers at the Ecole Polytechnique Fédérale de Lausanne (EPFL) have developed a new nanopore approach for manipulating individual molecules such as DNA that allows unprecedented control and precision. Read More
Eli Lilly acquiring immune therapy developer Dice Therapeutics for $2.4B
June 22, 2023 -- Eli Lilly said this week it has inked an agreement to acquire Dice Therapeutics, a biopharma firm developing novel oral therapeutic candidates, for $2.4 billion in cash. Read More
Biotech firm AltPep closes $53M Series B financing round
June 23, 2023 -- AltPep, a biotech firm developing early detection tests and disease-modifying treatments for amyloid diseases, on Friday announced the closing of a $52.9 million Series B financing round. Read More
usemap Join Us
Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter